Andrew Ninichuck, MD
General Practice · Bonne Terre, MONPI 1609841956
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by AbbVie at 48.2% of the total. Reporting peaked in 2021 at $1,569 and has fallen 72.8% since, to $427 in 2025. Among general practice clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Lilly USA, LLC$621
- Amarin Pharma, Inc.$485
- Amgen$285
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$228
- AstraZeneca$140
- plus $2K from 34 others
What the payments were for
- Food & beverage$6,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,585 in reported general payments places this provider in the 95th percentile of 1,446 general practice providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 163 | $199,296 |
| JardianceEmpagliflozin | 154 | $132,907 |
| VascepaIcosapent Ethyl | 209 | $108,108 |
| LinzessLinaclotide | 169 | $101,553 |
| OzempicSemaglutide | 91 | $94,868 |
| EliquisApixaban | 111 | $83,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $69,917 |
| MyrbetriqMirabegron | 89 | $47,592 |
| TrintellixVortioxetine Hydrobromide | 88 | $43,828 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 76 | $39,765 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $37,604 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 964 | $36,115 |
| Nurtec OdtRimegepant Sulfate | 22 | $30,504 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $28,053 |
| XareltoRivaroxaban | 32 | $24,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta | $124 | $199,971278 claims |
| Lilly USA, LLCMounjaro | $621 | $199,296163 claims |
| AbbVieLinzess, Ubrelvy, Namzaric, Savella | $3,173 | $125,535204 claims |
| PfizerEliquis, Nurtec Odt | $117 | $114,047133 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $88 | $108,599182 claims |
| Novo NordiskOzempic | $112 | $94,86891 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $55 | $53,539100 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $140 | $46,03078 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $24 | $43,82888 claims |
| Johnson & JohnsonXarelto, Invokana | $49 | $33,07246 claims |
| MerckJanuvia | $67 | $23,89727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,446 general practice providers in Missouri.
Other general practice in Bonne Terre
- Baron GrutterGladstone$445K
- Arthur GreenbergKansas City$241K
- Robert CalaluceColumbia$189K
- Suraiya SiddiqueMount Vernon$61K
- John FluckeLees Summit$60K
- Rex HudsonSaint Louis$49K
- David KaelinCape Girardeau$27K
- Nadeemuddin QureshiSaint Louis$22K
- Michael McKenzieHannibal$20K
- Robert McGrawCameron$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.